tuneTypical Dose
Protocol-defined topical use in trials (often once- to twice-daily application over weeks)
Peptide
GHK-Cu
Glycyl-L-histidyl-L-lysine copper complex
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Days to weeks for wound outcomes. 8-12 weeks for cosmetic appearance endpoints.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
GHK-Cu is a naturally occurring copper peptide used mainly for skin repair and cosmetic aging concerns. It is used to support collagen signaling, wound healing, and skin barrier function.
Topical studies support improved skin elasticity and firmness and reduced appearance of photodamage, consistent with extracellular matrix signaling effects. Evidence also supports improved wound healing and reduced local inflammation markers. Minority evidence suggests benefits for hair follicle biology in preclinical work. Systemic use lacks robust trials, so benefits are best supported for topical outcomes.
In vitro fibroblast and growth-factor modulation supports a tissue-support hypothesis. Clinical evidence is protocol-specific and strongest in controlled procedural or wound-care settings.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Wound closure
- Peri-procedural skin recovery
- Topical tolerability
Secondary Outcomes
- Skin texture/aging-related change signals
- Procedure satisfaction
Safety
Contraindications and Interactions
Contraindications
- Known copper/peptide allergy
- Pregnancy/lactation
- Severely unstable wound environments without specialist care
Side effects
- Injection site irritation
- Skin redness (topical)
Interactions
- Unverified topical peptide stack overlap
- Concurrent irritant/active skincare in open recovery phases
Avoid if
- Unsupervised ulcer care
- Persistent skin breakdown after initiation
- Severe eczema/dermatitis flare
Evidence
Study-level References
ghk-cu-SRC-001Narrative review with mechanistic synthesis.
Sourceopen_in_newPickart & Margolina. 2018. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 19(7): 1987. PMID: 29986520. PMCID: PMC6073405. DOI: 10.3390/ijms19071987.
Population: Collates cellular, animal, and limited clinical literature.
Dose protocol: Includes reviewed clinical reports and mechanistic datasets. Not a standardized dosing protocol.
Key findings: Supports biological plausibility of fibroblast, matrix, and wound/repair signaling. Identifies data as heterogeneous and often small- or protocol-specific.
Notes: Useful for mechanism context and uncertainty framing, not definitive dose-response guidance.
Paper content
Supports biological plausibility of fibroblast, matrix, and wound/repair signaling; identifies data as heterogeneous and often small- or protocol-specific.
ghk-cu-SRC-002Randomized controlled trial.
Sourceopen_in_newMiller TR et al. 2006. "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin." Arch Facial Plast Surg. 8(4): 252-259. PMID: 16847171. DOI: 10.1001/archfaci.8.4.252.
Population: Adults receiving CO2 laser resurfacing (n=13 completed).
Dose protocol: Topical post-resurfacing regimen with and without GHK-Cu. Exact concentration not provided in abstract.
Key findings: No objective difference in erythema resolution or objective wrinkle/appearance scores. Patient-reported skin quality improved (p = .04).
Notes: Limited sample and no protocol detail in abstract for dosing.
Paper content
No objective difference in erythema resolution or objective wrinkle/appearance scores; patient-reported skin quality improved (p = .04).
ghk-cu-SRC-003Randomized, evaluator-blinded, placebo-controlled clinical trial.
Sourceopen_in_newMulder GD et al. 1994. "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper." Wound Repair Regen. 2(4): 259-269. PMID: 17147644. DOI: 10.1046/j.1524-475X.1994.20406.x.
Population: Adults with diabetic neuropathic plantar ulcers.
Dose protocol: Daily metered topical application in a standardized protocol including debridement, pressure-relieving footwear, and diabetes care education.
Key findings: Median area closure 98.5% vs 60.8% with vehicle. Closure rate approximately triple. Infection 7% vs 34% with vehicle.
Notes: Older study. Concentration details and full protocol specifics are limited in abstract.
Paper content
Median area closure 98.5% vs 60.8% with vehicle; closure rate approximately triple; infection 7% vs 34% with vehicle.
ghk-cu-SRC-004Comparative in vitro study.
Sourceopen_in_newPollard JD et al. 2005. "Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts." Arch Facial Plast Surg. 7(1): 27-31. PMID: 15655171. DOI: 10.1001/archfaci.7.1.27.
Population: Normal and irradiated primary human dermal fibroblasts.
Dose protocol: 1 x 10^-9 mol/L GHK-Cu in vitro.
Key findings: Faster fibroblast doubling in treated groups and early increases in bFGF/VEGF relative to untreated control.
Notes: Not a clinical efficacy endpoint.
Paper content
Faster fibroblast doubling in treated groups and early increases in bFGF/VEGF relative to untreated control.
ghk-cu-SRC-005Comparative in vitro study.
Sourceopen_in_newMcCormack MC et al. 2001. "The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model." Arch Facial Plast Surg. 3(1): 28-32. PMID: 11176716.
Population: Dermal fibroblasts (normal and keloid-producing).
Dose protocol: Copper tripeptide 1 x 10^-9 mol/L in vitro.
Key findings: Lower TGF-beta1 secretion in treated fibroblasts, suggesting mechanistic scar-modulation potential.
Notes: No direct clinical outcome translation.
Paper content
Lower TGF-beta1 secretion in treated fibroblasts, suggesting mechanistic scar-modulation potential.
ghk-cu-SRC-006Randomized controlled trial.
Sourceopen_in_newWang JV et al. 2020. "Tripeptide and hexapeptide topical as adjunct to nonablative fractional resurfacing for photodamage: a randomized split-face trial." J Cosmet Dermatol. 19(12): 3245-3250. PMID: 33051975. DOI: 10.1111/jocd.13795.
Population: Adults undergoing nonablative fractional resurfacing.
Dose protocol: Topical tripeptide/hexapeptide serum vs moisturizer, twice daily from 14 days pre-treatment through 60 days post. Serum composition includes peptide blend.
Key findings: Greater improvement in photodamage/texture measures and no significant adverse events.
Notes: Not isolated to GHK-Cu and not dose-standardizable for GHK-Cu alone.
Paper content
Greater improvement in photodamage/texture measures and no significant adverse events.
ghk-cu-SRC-007Narrative review
Sourceopen_in_newDou Y et al. 2020. "The potential of GHK as an anti-aging peptide." Aging Pathobiology and Therapeutics. 2(1):58-61. PMID: 35083444. DOI: 10.31491/apt.2020.03.014.
Population: Review of mechanistic, preclinical, and limited human skin and wound-healing literature.
Dose protocol: Review-level source summarizing heterogeneous topical, wound, and mechanistic literature.
Key findings: Supports age-related decline in endogenous GHK and plausible repair signaling, but does not provide new direct efficacy evidence for injected anti-aging use.
Notes: Useful for scope control and marketing-claim correction, not for quantitative effect sizing.
Paper content
Review-level evidence supports age-related decline in endogenous GHK and a plausible tissue-repair, anti-inflammatory, and skin-remodeling signal, but it does not create new direct efficacy evidence for injected anti-aging use.